Home > Insider Trading > Filing (0001209191-15-043845)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1373707	Tetraphase Pharmaceuticals Inc	TTPH	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1572000	Charles David Lubner	480 Arsenal St. Suite 110 Watertown MA 02472	Svp And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-05-14	7,684	$2.03	86,954	No	4	M	Direct
Common Stock	Disposition	2015-05-14	7,684	$39.28	79,270	No	4	S	Direct
Common Stock	Acquisiton	2015-05-14	7,316	$2.03	86,586	No	4	M	Direct
Common Stock	Disposition	2015-05-14	7,316	$39.28	79,270	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2015-05-14	7,684	$0.00	7,684	$2.03
Common Stock	Employee Stock Option (right to buy)	Disposition	2015-05-14	7,316	$0.00	7,316	$2.03

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2020-09-27	No	4	M	Direct
27,043		2022-06-05	No	4	M	Direct

Footnotes

The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2015.
The amount of securities beneficially owned by the reporting person following the transaction reported on this Form 4 reflects the purchase by the reporting person of 402 shares of common stock on November 17, 2014 and 405 shares of common stock on May 14, 2015. Both of these purchases were done under the issuer's 2014 Employee Stock Purchase Plan ("ESPP"). The shares purchased in November 2014 under the ESPP were inadvertently omitted from the amount of securities beneficially owned that were reported on the Form 4 filed by the reporting person on January 9, 2015.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $38.03 to $39.89 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This option is fully vested.
This option vests as to 6.25% of the shares on September 6, 2012 and further vests as to 6.25% of the shares at the end of each of successive three-month period thereafter until June 6, 2016.